FDA clearance opens up new opportunities for MedApp S.A. in the US market.

We are pleased to report that we have just returned from one of the largest medical technology trade shows in the world – HIMSS24 in Orlando, Florida. From the perspective of our expansion into the US market it was an extremely important event and a very intense few days.

The purpose of our presence at HIMSS24 was to present CarnaLife Holo to potential customers and partners from the medical industry around the world, with a strong focus on the US. These were very fruitful days – we held dozens of meetings that may bring real business and financial benefits in the near future. The most important stage begins now, right after the conference, as we follow up with potential customers and exchange knowledge and experience with new international partners.

We are pleased with the large number of conversations held with physicians, representatives of medical training centres and universities, venture capital funds, people from the business and M&A community, distributors, innovation managers and directors, representatives of the US administration, start-up founders, software service providers and many other stakeholders from the wider medical market representing North America, Europe and Asia.

For visitors to our booth, a key factor was our FDA clearance admitting our technology to the US market. It set us apart from many of the companies presenting at the event which, unlike MedApp S.A., have not yet received Food and Drug Administration approval to commercialise their solutions in the United States.

HIMSS24 in Orlando proved to be an excellent place to make new business contacts and present our mixed reality 3D holographic imaging technology, CarnaLife Holo. The event exceeded our expectations in terms of organisation, business and the scale of interest in our software!

Taking part in HIMSS24 confirmed our belief that MedApp S.A.'s strategic place is in the US.